Regarding the stopped phase III glioblastoma trial with Rintega (rindopepimut), Celldex Therapeutics Inc. CEO Anthony Marucci said the firm is "well positioned to weather this temporary setback," and during the weeks ahead will ransack data from ACT IV for clues to why control arm patients did just as well as those on the drug.